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Data from 142 patients who had sustained ventricular
tachycardia or ventricular fibrillation were analyzed to
determine if clinical variables predict response to
antiarrhythmic drugs at c1ectrophysiologic study. Effec-
tive antiarrhythmic drugs were identified for 43 patients
(30%). Ten of 25 variables analyzed were univariate
predictors of drug response at the probability (p) level
of less than 0.05. Stepwise logistic regression identified
three variables independently predictive of drug re-
sponse: fewer coronary arteries with 70% or greater
stenosis (p <O.OOI), female sex (p <0.002) and fewer ep-
isodes of arrhythmia (p<0.03). A function incorporating
these three variables was constructed to predict the prob-
ability of drug response, and ranges of the predictor
Pharmacologic trials during electrophysiologic studies have
been reported to predict efficacy and inefficacy of antiar-
rhythmic drugs during subsequent oral therapy (1-3). How-
ever, electrophysiologic-pharmacologic studies are long. in-
vasive and expensive. Effective drugs are not identified for
many patients (4-8), and some drugs predicted to be in-
effective may prevent clinical arrhythmia recurrence (2,7,9).
Because alternative methods for selection of pharmacologic
(10-13 ) and nonpharmacologic (14-18 ) antiarrhythmic
therapy exist. prospective identification of those patient s
most likely to benefit from electrophysiologic-pharmaco-
logic study would be desirable . We therefore analyzed clin-
ical data from patients who underwent electrophysiologic-
pharmacologic study to determine if any clinical variables
can be used to predict those patients for whom effective
antiarrhythmic drugs will be identified and those for whom
no effective drug can be found.
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function corresponding to high, intermediate and low
probabilities of drug response were identified. Response
rates in the high (>50%), intermediate and low «10%)
probability ranges were 28 (58 %) of 48, J0 (27 %) of 37
and 5 (9%) of 57, respectively. Thus 40 % of the patients
who had a less than 10 % likelihood of benefit from elec-
trophysiologic-pharmacologic study were c1assfied into
the low probability range. When the predictor function
was applied prospectively to 25 additional patients, re-
sponse rates in the three probability ranges were 3 (50 % )
of 6, 1 (12%) of 8 and 0 (0%) of 11. These data show
that analysis of clinical variables can be used to estimate
the probability of benefit from electrophysiologic-phar-
macologic study.
Methods
Study patients and clinical variables. Drug trials were per-
formed using a uniform programmed stimul ation protocol in 142
patients who had spontaneous and inducibl e sustained ventricular
tachycardia or ventricular fibrillation not associated with acute
myocardi al infarction. Their clinical characteristics are summa-
rized in Table I A. Twenty-five clinical variables chosen for their
relation to underl ying cardiac disease and clin ical arrhythmias were
selected for analysis . The demographic variables were age and
sex. Variables relating to cardiac disease were absence of structural
heart disease . valvular heart disease , myocardial disease, coronary
artery disease, infarct location and date . cardiac surgery and New
York Heart Association functional class. The clin ical arrhythmia
characteristics analyzed were rate, symptoms,* time from onset
(months), number of episodes, number of unsuccessful empiric
antiarrhythmic drug trials, number of hospit alizations , requirement
for cardioversion , requirement for cardiopulmonary resuscitation
and ventricular fibrillation. Catheterization and angiographic vari-
ables were left ventricular end-d iastolic pressure, cardiac index.
left ventricular ejection fraction, left ventncular aneur ysm presence
*An arrhythmia-symptom score based on eac h patien t' s most severe
arrhythmia-rela ted symptom was defined a, follows . palpitation ( I pomt ):
dyspn ea, angina or presyncope (2 pomrs): syncope (3 pomts) : cardiac arrest
(4 point s)
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Table 1. Clinica l CharacterislIcs
Patients (no.)
Age (yr)
Male/female rauo
Cardiac disease
CAD
Previous MI
Left ventnc ular aneurysm
Myocardial disease
Valvular disease
No structural heart disease
CA with ;;:: 70% stenosis
Arrhythmia characten stics
Sustained VT
Ventricular fibrillation
Cardroversron required
Cardiac arrest
Unsuccessful EDT (no .)
Hospitalizations (no)
Episodes (no . )
Left ventricular function
LVEDP (torr)
CI (liters/min per m' )
LVEF
NYHA class
I
II
III
IV
Original
Panents
142
57 ± 13
4 .5 :1
102(72)
97(68)
63(44)
13(9)
8(6 )
19(12 )
1.6 ± I
136(96)
6(4)
112(79)
45(32)
3.5 ± 2 . 1
2.9 ± 2.3
5.5 ± 3.2
17 ± 9( n = 130)
2.4 ± 07 (n= 128)
0 .36 ± 0 . 15 (n = 126)
28(20 )
56(39)
48(3 4)
10(7)
A
Prospective
Pancnts
25
60 ± II
24 :1
19(76)
18(72)
8(32)
5(20)
1(4)
0(0)
20 ±1.2
2 1(84)
4(\6)
23(92)
12(48)
3 3 ± 2.2
2 . 1 ± 22
5 .2 =4 . 1
17 ± 9 (n =24)
2 6± 0 8( n= 23)
0 .36 ::': 0 . 13 (n=23 )
7(28)
11(44)
6(24)
1(4)
Onginal
Patients'
Responders
43
53 ± 17*
2. 1.1*
25(58) :'
24( 56) '
12(28)'
6(\4)
1(2)
11(26) "
I I ± 1.0 :
39(91 )
4(9 )
3 1(72)
16(37)
3 1 ± 2.2 :
2 .7 ± 2.2
5. 1 ± 35 :'
16 ::': 10 In= 35)
25 ± 0 7 (n= 38 )
0 39 ± 0 . 16(n =34)
13(30) '
15(35 )
14(33)
1(2)
B
Onginal
Patients.
Nonresponders
99
58 ± 11*
7 .3 ' 1'
77(77)"
73(74 )'
51(52 )"
7(7 )
7(7)
wn"
1.7 ± 1'-
97(9 8)
2(2)
8 1(82)
29(29)
3.6 ± 2 . 1"
29 ± 23
5 7 ± 3 I :'
18 :!: 9 (n = 95)
24 :!: 0 7 (n = 90)
0 .34 :!: 0 14 (n =92)
15(15 )*
4 1(42)
34(34)
9(9)
*p < 005
Numbers In parentheses are percent values CA = coronary artenes, CAD = coronary artery disease: Cl = cardiac Index. EDT = ernpmc drug tnal s, LV = left
ventricular. LVEDP = left ventricular end-diastolic pressure. LVEF = left ventricular ejecuo n fraction. MI = myocardial infarction. NYHA = New York Heart Assocrauon ,
VT = ventricular tachycardia
and location and number of coronary arte ries with 70% or greater
stenos is.*
Absence of structural heart disease was diagnosed if physical
examinatio n. restin g electrocardiogram . chest X-ray film. two -
dimen sional ec hocardiograrn, exe rcise treadmill test and end o-
myocard ial biopsy reveal ed no evi de nce of structural heart disease .
Complete hem odynamic and angiographic evaluation. including
co ntras t le ft and right ventriculog raphy and coronary arteriog-
raph y. was performed whenever this diagnosis was in quest ion .
Valvular heart disease was diagnosed if patient s had hem ody-
nam icall y significant sten osis or insufficiency of one or more
cardi ac valves . or both auscultatory and ec hoca rdiographic finding s
of mitral valve prolapse or previou s valve surge ry . Myocardial
disease was diagnosed if cardiac enlarge ment or left ventricular
hypert roph y or dilation was documented by echocardiography or
contras t angiography in the absen ce of coron ary artery disease or
valvular heart disease. The presence of hypertrophy and fibrosis
*Disease of the left main coronary artery was considered as two vessel
disease In right dominant coronary artery systems and three vessel disease
In left dommant coronary artery systems.
on end omyocardial biopsy was used as evidence confirming myo-
cardi al disease . Coronary artery di sease was diagnosed if the di-
ameter of at least one major coronary artery was narrowed by 70%
or more . Myocardial infarction was d iagnosed on the bas is of
characteristic evo lutionary electrocardi ographic and enzyme changes
or by the presence of pathol ogic Q waves In two or more electro-
cardiographic leads . Left ventricular aneurys m was diagnosed if
one or more dyskin etic seg ments were ident ified by contrast
ventric ulography.
Left ventricular ejection f raction was determined by contras t
ventriculog raphy in the 30° right anterio r oblique projection . The
left ventricular end-diastoli c pressure was measured before ang i-
og raphy . Coronary angiograph y was performed In 131 patient s .
C linica l d iagno ses in the II patient s who did not undergo coronary
angiography included absence of structural heart disease (n = 8>.
Isolated mitral valve prolapse (n = 2) and dilated cardio myo pathy
(n = 1). Ten of these 11 patients were younge r than 30 years of
age . and the 11th was 46 yea rs old . All had a normal resting
electrocardiogram and norm al ST segment and T wave response
to exercise treadmill testing . They were assumed to have no cor-
onary artery stenoses of 70% or greater
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Empiric trials of antiarrhythmic drugs were considered "un-
successful" only if arrhythmia recurred during adequate dosing or
if toxicity required discontinuation of the drug.
Electrophysiologic study protocol. All antiarrhythmic med-
ications except digoxin were discontinued at least 24 hours before
initial electrophysiologic study. r A strict protocol for programmed
stimulation and antiarrhythmic drug assessment was followed" (2).
It included up to three right ventricular extrastimuli in sinus and
ventricular paced rhythms at multiple basic pacing cycle lengths,
bursts of rapid ventricular pacing to a cycle length of 200 ms and,
when necessary, use of a second right ventricular site and isopro-
terenol infusion (2,7). Arrhythmia induction and drug assessment
by left ventricular stimulation were not analyzed because they were
not performed routinely early in this series. In the baseline state,
all patients had inducible, sustained ventricular tachycardia (> 15
s) or ventricular fibrillation. All pacing methods were used before
a drug was Judged effective, regardless of the complexity of the
program ~:-'Ul induced ventricular tachycardia in the control state.
An antiarrhythmic drug was considered effective if no more than
five repetitive ventricular complexes could be initiated after admin-
istration. Drug trials were terminated when one effective drug
suitable for oral therapy was identified. At electrophysiologic-
pharmacologic study, patients were considered "responders" if at
least one effective drug was identified and' 'nonresponders" if no
effective drug was identified.
Statistical analysis. Basic comparative statistics were calcu-
lated using the chi-square test with Yates' correction, Fisher's exact
test or the two-tailed t test for independent means. Continuous
data are presented as mean ± I standard deviation.
The 25 independent clinical variables were evaluated by uni-
variate logistic regression analysis for their strength of association
with the dependent variable, successful electrophysiologic-phar-
macologic study. When missing values for hemodynamic and an-
giographic variables occurred, univariate analysis was restricted
to those patients for whom values were defined, except for the II
patients assumed to have no coronary artery stenosis of 70% or
greater. This analysis generated a chi-square value from which a
probability value was calculated.
Because no single variable adequately separated responders
from nonresponders, forward, stepwise logistic regression was
applied to variables selected as the most discriminative (p < 0.10)
"Serum digoxin concentration was not mcluded m the 25 clinical vari-
ables we analyzed. Approximately 30% of our patients were receiving
digoxin at the time of their electrophysiologic studies. Because the value
of this variable is zero for approximately 70% of our patients, the logistic
regression technique we used would be relatively insensitive to any dose-
related effect of digoxin on the outcome of clcctrophysiologic-pharma-
cologie studies.
*We administered antiarrhythmic drugs according to a previously de-
scribed protocol (2) and determined antiarrhythmic drug plasma concen-
trations at the terrninanon of each study. Both intravenous and oral drug
trials were analyzed. Some patients did not receive the full Intravenous
loading doses of all drugs mdicated in the protocol because of dose-related
toxicity. We evaluated drugs administered orally only after therapeutic
plasma concentrations were achieved. We evaluated drugs for which plasma
concentrations were not determined routinely only after dose-related tox-
icity precluded dose increases (tocainide or mexilitene), dose-related elec-
trocardiograpluc changes had occurred (encamide) or the maximal dose in
our protocol had been administered for a sufficient penod of time (lorcainide)
on the basis of univariate analysis to construct a multivariate pre-
dictor function (19). All variables that predicted drug response at
the level p < 0.10 proved to be predictive at the level p < 0.05.
None of these univariate predictors had missing values. The final
multivariate predictor function we selected included all variables
with significant, independent predictive value, corresponding to a
level p < 0.05 (see Appendix). Sensitivity, specificity, positive
predictive value and negative predictive value for univariate and
multivariate predictor functions were calculated according to stan-
dard definitions (20). For validation, the multivariate predictor
function was applied prospectively to the next 25 consecutive
patients with sustained ventricular tachycardia or ventricular fi-
brillation who underwent electrophysiologic-pharmacologic study.
Results
Overall, 442 trials of single antiarrhythmic drugs and
134 trials of antiarrhythmic drug combinations were per-
formed. The mean number of trials per patient was 4.0 ±
1.8 (range I to II). Acutely effective drugs were identified
for 43 (30.3%) of 142 patients.
Univariate predictors of drug response. Clinical char-
acteristics of responders and nonresponders are compared
in Table l B. Table 2 lists univariate predictors of drug
response at the level p < 0.05 and shows the sensitivity,
specificity, positive predictive value and negative predictive
value of univariate predictor functions based on these vari-
ables. Patients were predicted to be responders if the pre-
dicted probability of drug response was greater than the
mean response rate for the entire population (30.3%). Sev-
eral variables relating to demographic factors, structural
heart disease and the clinical arrhythmia correlated with
response or nonresponse. The predictive influence of vari-
ables related directly or indirectly to drug refractoriness of
the clinical arrhythmia (as judged by greater number of
unsuccessful empiric drug trials, greater number of clinical
arrhythmia episodes and longer time from initial arrhythmia
episode) was not a result of fewer electrophysiologic-phar-
macologic trials performed in these patients. The respective
coefficients of correlation with number of electrophysio-
logic-pharmacologic trials for the above three arrhythmia-
related variables were: r = - 0.11, r = - 0.15 and r =
0.10 (p > 0.10 for all coefficients of correlation).
Multivariate predictor function. Because no single
variable was both highly sensitive and highly specific, for-
ward logistic regression was applied to the variables listed
in Table 2 to construct a multivariate predictor function.
Variables chosen for this function, in the order selected by
the regression, were fewer coronary arteries with 70% or
greater stenosis (chi-square = 12.59, P = 0.0004), female
sex (chi-square = 9.98, p = 0.0016) and fewer number
of arrhythmia episodes (chi-square = 4.85, P = 0.0277).
The expected probability of drug response based on this
function can be calculated for each patient as shown in the
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Table 2. Univariate Predictors of Drug Response
Positive Negative
Predictive Predictive
Value Value
Chi-square p Value Sensitivity (%) Specificity (%) (%) (0/,)
Demographic
Female sex 9,16 0.0025 33 90 58 75
Younger age 4,45 0.0349 56 62 39 76
Structural heart disease
No structural
heart disease 6,70 0.0096 26 92 58 74
No coronary
artery disease 9,57 0.0020 42 80 47 76
NYHA functional
class 4,68 0,0305 65 43 33 74
Fewer coronary arteries
with 2: 70% stenosis 18,43 <0,0001 81 52 42 86
No left ventncular aneurysm 6,17 0,0130 74 48 38 81
Clinical arrhythmia
Fewer arrhythmia episodes 4.05 0,0042 60 70 40 84
Fewer unsuccessful empiric
drug trials 4,53 0,0333 54 58 35 74
Time from arrhythmia
onset (months) 5,50 0.0191 38 74 38 74
NYHA = New York Heart Association; p = probability
Appendix. Figure 1 displays the expected probability and
observed incidence of drug response for all 142 patients.
The multivariate predictor function had 70% sensitivity,
70% specificity, a 52% positive predictive value and an
81% negative predictive value. High, intermediate and low
probability ranges were established to improve the utility
of the predictor function so that the incidence rate of drug
response was greater than 50% in patients classified in the
high probability range and less than 10% in patients clas-
sified in the low probability range. The actual response rates
were 28 (58%) of 48 in the high probability group, 10 (27%)
of 37 in the intermediate probability group and 5 (9%) of
57 in the low probability group (Fig. 2). Overall, 105 (74%)
of 142 patients were in the low or high probability group.
In the high probability range, the predictor function had
65% sensitivity, 80% specificity, a 52% positive predictive
value and an 84% negative predictive value. In the low
probability range, it had 88% sensitivity, 53% specificity,
a 92% positive predictive value and a 45% negative pre-
dictive value.
Figure I. The probability of drug response
IS plotted on the ordinate and the value of
the legit function as defined In the Appen-
dix IS plotted on the abscissa, The contin-
uous curve represents the estimated prob-
ability of drug response calculated from thc
predictor function, The triangles represent
the observed probabihty of drug response
computed for specific values of the logit
function, The values of the logit function
for each of the 43 responders arc shown by
the open squares at the top, The value, of
the logit function for each of the 99 non-
responders are shown by the closed circles
at the bottom, The vertical lines indicate
the cutoff pomt-, used to classify patients
Into groups having a high. Intermediate or
low probability of drug response
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Figure 2. The incidence of drug response in each of the three probability
groups is shown for the original population of 142 patients. Responders
are represented by the shaded areas in the bar graph: nonresponders are
represented by the white areas in the bar graph The mcidence rate of
drug success was 58% m the high probability group. 27o/c in the inter-
mediate probability group and 9% in the low probability group. The num-
bers within the bar graphs refer to numbers of patients.
Prospective study. The validit y of the predictor func-
tion was assessed by prospecti ve application to 25 patient s.
Clinical characteristics of the original and prospective pa-
tients are compared in Tabl e IA; there are no statistically
significant differences. Effective drug s were identified for
4 (16%) of the 25 prospective patients. Response rates in
the high, intermediate and low probability groups were 3
(50%) of 6, I (12%) of 8 and 0 (0%) of II, respectively,
when the probability ranges select ed for the original pop-
ulation were used (Fig. 3). If electrophys iologic-pharma-
cologie study had not been performed in patients in the low
probability group, only five (12%) of the responders in the
original population and none (0%) of the responders in the
prospective popul ation would have been excluded from elec-
trophysiologic-pharmacologic study, and the associated risks
and discomforts would have been avoided in 52 (53%) non-
responders in the original populati on and II (53%) nonre-
sponders in the prospecti ve population.
Discussion
Comparison with previous studies. The purpo se of this
study was to identify clini cal variables associated with drug
response and nonresponse , so that these variables could be
used to select the patients most likely to benefit from elec-
trophysiologic-pharmacologic study. Previously reported data
relating clinical variables to drug response are limited.
Garson and Gillette (21) reported that chronic ventricular
Figure 3. Prospective analysis in 25 patients of the incidence of drug
response in each of the three probability groups is shown. Symbols are
the same as those used in Figure 2. The mcidence rate of drug response
was 50% in the high probability group, 12% in the intermediate probabilit y
group and 0% in the low probability group. The numbers within the bar
graphs refer to numbers of patients.
arrhythmias were controlled more frequently by antiar-
rhythm ic drugs in children with severely abnormal hemo-
dynamic s than in those with mildly abnormal or normal
hemodynamics when response was assessed by suppre ssion
of spontaneous or exercise-induced premature ventricular
complexes . Phenytoin , the most frequently used agent in
their series (51 of 65 drug trial s , 78%), was rarely used in
ours (2 of 576 drug trials, 0.3%). Their study protocol
provided for treatment of less compl ex arrhythmias in pa-
tient s with more severe structural heart disease.
Swiryn et al. (8) analyzed factors predicting drug re-
sponse at electrophysiolo gic study in 41 patients who had
recurrent ventricular tachy cardi a or ventricular fibrillation .
In thei r analysis, the only variable that correlated signifi-
cantly with drug response was fewer previou s empiric drug
trials. Th is correlation also occurs in our data . The study
by Swiryn et al. differs from ours in the stimulation protocol
used, definit ion of drug respon se, antiarrhythmic drugs ana-
lyzed and size of the study population . Swiryn and co-
workers used a third extrastimulus occasionally; we used
one uniforml y. Their criterion for drug respon se was less
than 2 minutes of induced ventricular tachycardia; our cri-
terion was less than six co mplexes. The y analyzed only
respon se to type I antiarrhythmic drug s; we analyzed re-
sponse to all classes of antiarrhythmic drugs . Their patient
population was less than one-third the size of ours and may
have been too small to detect some differences between
responders and nonresponders (type II error). Trends toward
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a greater incidence of drug response in younger patients,
those who did not have coronary artery disease and those
who had a shorter duration of symptoms are present in their
data, but they are not statistically significant. These trends
reach significance in our larger patient population,
Multivariate predictor function: predictive accuracy
of drug response. In our study, several individual variables
correlated with drug response, but none was sufficiently
predictive to be clinically useful. We therefore used forward
logistic regression to select a multivariate predictor function
based on those variables that best predicted drug response
independently: fewer coronary aheries with 70% or greater
lesions, female sex and fewer episodes of arrhythmia, The
function's accuracy was verified by prospective application
to a new patient population,
By using this function. patients were classified into three
groups based on the probability of drug response. In the
low probability group, the response rates in the original
population (9%) and in the prospective population (0%)
were sufficiently low that we believe electrophysiologic-
pharmacologic study can be withheld reasonably from such
patients. We believe that the incidence of drug response in
patients in the intermediate probability group is sufficiently
great to warrant electrophysiologic-pharmacologic studies
in most of them, The expected probability of identifying an
effective drug for any giveh patient can be calculated as
shown in the Appendix. This estimate should be considered
with other clinical factors to determine whether electro-
physiologic-pharmacologic study should be used to select
antiarrhythmic therapy.
Role of left ventricular dysfunction and coronary ar-
tery disease. In our study, several measures of less severe
structural heart disease correlated with successful electro-
physiologic-pharmacologic study: absence of structural heart
disease, absence of coronary artery disease, lower New
York Heart Association functional class, absence of left
ventricular aneurysm and fewer coronary arteries with 70%
or greater stenosis. The first variable selected by the regres-
sion, number of coronary arteries with 70% or greater ste-
nosis, is an indirect measure of left ventricular function in
our patients. Subjects with no structural heart disease, who
had a large incidence of drug response, all received a score
of 0, whereas almost all patients with coronary artery disease
in our study had had one or more previous myocardial in-
farctions and therefore had some degree of left ventricular
dysfunction.
Although no angiographic or hemodynamic measures of
left ventricular function separated responders from nonre-
sponders, our catheterization data may be biased. Eight of
the 19 patients with no structural heart disease and 2 patients
with isolated mitral valve prolapse did not undergo left heart
catheterization or coronary angiography. This group had a
high incidence of drug response. If complete catheterization
data had been available for all of these patients, the insig-
nificant observed differences in left ventricular end-diastolic
pressure, cardiac index and left ventricular ejection fraction
between responders and nonresponders would have been
greater and might have achieved statistical significance.
A high incidence of sudden death has been reported in
patients with coronary artery disease who have both ven-
tricular arrhythmias and left ventricular dysfunction (22-
24). Such patients frequently are treated with antiarrhythmic
drugs in an attempt to prevent arrhythmic death. Our data
correlating the extent of coronary artery disease with drug
inefficacy suggest that antiarrhythmic drugs are least likely
to be predicted effective at electrophysiologic-pharmaco-
logic study in those patients who are at the greatest risk for
sudden death.
Several direct or indirect measures ofdrug refractoriness
of the clinical arrhythmia were correlated with unsuccessful
electrophysiologic-pharmacologic study in our patients. These
variables included greater number of unsuccessful empiric
drug trials, greater number of clinical arrhythmia episodes
and longer time from the initial arrhythmia episode. Their
predictive value was not simply due to exhaustion of agents
available for drug trials; the number of arrhythmia episodes
was selected by the regression as independently predictive
of unsuccessful electrophysiologic-pharmacologic study.
We have no explanation for the observed association of
female sex with drug response independent of factors related
to severity of structural heart disease and previous drug
refractoriness. This association may have occurred by chance,
because only 27 women were included in our study group.
However, the strength of association is so great (p = 0.0016)
that it is unlikely that the correlation was due to chance
alone.
Study limitations. Our study has several limitations.
For the purpose of this analysis, 11 patients who did not
undergo coronary arteriography were assumed to have no
coronary artery stenosis of 70% or greater. It is possible,
but unlikely, that this assumption was incorrect for one or
more of these patients. Most of our patients were referred
for electrophysiologic study only after several episodes of
recurrent ventricular tachycardia and one or more trials of
antiarrhythmic drug therapy. We do not know if a similar
regression can be developed for patients who present with
a first episode of ventricular tachycardia. The regression
applies specifically to pharmacologic trials performed ac-
cording to the pacing protocol used in our laboratory. The
incidence of drug response has been greater in studies in
which response was assessed using a maximum of two ex-
trastimuli (1,3,7); thus, the regression might not be accurate
for other pacing protocols. Also, the logistic regression tech-
nique is insensitive to predictive variables that have a very
low prevalence in the patient analyzed; our predictor func-
tion might not be applicable to a very different patient group.
However, our patients are similar to previously described
groups of patients with ventricular tachycardia (3,8,25,26).
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APPENDIX
The logistic regression model assumes that the probability (Pj)
of successful electrophysiologic-pharmacologic study for the jth
patient can be expressed by the function:
where Xlp X2p ... , xnJ are the values of clinical variables corre-
sponding to the jth patient and f3<j,f3J,' .. ,f3n are unknown weights.
The objective of this technique is to maximize separation of
two or more groups by combining variables with appropriate
weighting factors. The single most predictive variable is selected
first. Remaining variables are then added in a stepwise manner
according to their ability to improve prediction. At each step, all
remaining variables are examined, and the variable that provides
the greatest marginal contribution to the further discrimination is
selected. Additional variables are included until no variable re-
mains that improves discrimination at a chosen levelof significance
(p).
I + ellXl32
= 0.73.
p
logit = -1.1177 - 0.7336(1) + 1.7043(2) - 0.1847(3)
= 1.0032.
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